Clinical insight is not a go-to-market strategy; clinician-founders need to stage proof, payment and access in the order their market actually requires.
AI-native devices shift value from hardware margin to repeated clinical inference, changing cost structure, pricing power, regulatory burden and venture underwriting.
The right sequence depends on who changes behavior, who bears risk, and who captures savings—not on which milestone looks most fundable this quarter.